Pelthos Therapeutics Inc. has acquired Xepi® (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, expanding its dermatology portfolio alongside its novel molluscum contagiosum treatment, ZELSUVMI™. Xepi addresses a critical unmet need in antibiotic-resistant skin infections, particularly those caused by staph and strep bacteria, and is most commonly used in pediatric patients. The company plans to relaunch Xepi in the U.S. and will use proceeds from a recently completed $18 million private convertible notes financing to support the acquisition, as well as to accelerate commercialization efforts for ZELSUVMI and for general working capital.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-25-001715), on November 07, 2025, and is solely responsible for the information contained therein.